La vendita allo scoperto per BioLine Rx dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioLine Rx. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioLine Rx (NASDAQ:BLRX) Azioni, Report sulle vendite allo scoperto

BIOLINERX LTD-SPONS ADR

BioLine Rx

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

In the latest quarter, 4 analysts provided ratings for BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for BioLine Rx, revealing an average target of $22.5, a high estimate of $26.00, and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 10.67% increase from the previous average price target of $20.33.
<img src="https://www.benzinga.com/files/images/story/2025/1750161649_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive BioLine Rx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Justin Walsh</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BioLine Rx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioLine Rx compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioLine Rx's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of BioLine Rx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BLRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BioLine Rx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About BioLine Rx</h2>
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
<h3>A Deep Dive into BioLine Rx's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, BioLine Rx faced challenges, resulting in a decline of approximately -96.28% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioLine Rx's net margin is impressive, surpassing industry averages. With a net margin of 2010.59%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): BioLine Rx's ROE stands out, surpassing industry averages. With an impressive ROE of 29.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): BioLine Rx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.44%, the company showcases efficient use of assets and strong financial health.
Debt Management: BioLine Rx's debt-to-equity ratio stands notably higher than the industry average, reaching 0.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BLRX

Where BioLine Rx Stands With Analysts

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) with a Buy and maintains $26 price target.

News

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target

<h3>Gainers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 142.0% to $0.5 during Monday's pre-market session. The market value of their outstanding shares is at $16.1 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 103.2% to $3.17. The market value of their outstanding shares is at $23.7 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock increased by 30.37% to $10.75. The company's market cap stands at $39.5 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock increased by 16.4% to $32.0. The company's market cap stands at $3.3 billion. </li>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) stock moved upwards by 14.32% to $8.22. The company's market cap stands at $432.3 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares increased by 12.71% to $6.47. The market value of their outstanding shares is at $24.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) shares declined by 23.9% to $2.51 during Monday's pre-market session. The company's market cap stands at $46.9 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 15.28% to $20.52. The company's market cap stands at $533.8 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 13.77% to $0.94. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 13.55% to $0.5. The market value of their outstanding shares is at $3.6 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 9.91% to $0.17. The market value of their outstanding shares is at $11.2 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock declined by 8.28% to $0.72. The company's market cap stands at $56.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLSD

GLYC

HSDT

JBIO

KLRS

KLTO

LIMN

MTSR

SILO

Tempest Therapeutics, Inc. - Common Stock

TPST

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock rose 376.8% to $23.5 during Monday's regular session. The market value of their outstanding shares is at $31.1 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock increased by 64.08% to $31.09. The company's market cap stands at $1.9 billion. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock rose 59.82% to $1.79. The company's market cap stands at $25.6 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares rose 58.0% to $0.95. The company's market cap stands at $74.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 56.58% to $0.46. The company's market cap stands at $5.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 40.92% to $0.4. The company's market cap stands at $2.3 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock declined by 31.2% to $0.74 during Monday's regular session. The company's market cap stands at $38.1 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 27.47% to $4.41. The company's market cap stands at $82.8 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 19.24% to $4.24. The market value of their outstanding shares is at $15.7 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares decreased by 18.82% to $6.11. The company's market cap stands at $335.4 million. </li>
<li>TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) stock declined by 17.81% to $1.2. The market value of their outstanding shares is at $13.8 million. </li>
<li>Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) stock fell 16.1% to $4.43. The market value of their outstanding shares is at $303.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

HYPR

LYRA

MODV

OLMA

PCSA

PSTV

TXMD

VERA

VSTM

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging higher on Friday.
The Dow traded up 0.05% to 42,238.88 while the NASDAQ fell 0.74% to 19,033.46. The S&amp;P 500 also fell, dropping, 0.24% to 5,898.22.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Consumer staples shares jumped by 1% on Friday.
In trading on Friday, information technology stocks fell by 1.5%.
Top Headline
Shares of Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell more than 3% on Friday after the company reported mixed financial results for the first quarter.
Dell reported first-quarter revenue of $23.38 billion, beating the consensus estimate of $23.14 billion, according to Benzinga Pro. The company reported adjusted earnings of $1.55 per share, missing analyst estimates of $1.69 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Universal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVV#NYSE">UVV</a>) shares shot up 11% to $65.96 following quarterly results.</li>
<li>Shares of Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) got a boost, surging 11% to $470.18 after the company reported better-than-expected first-quarter financial results and raised guidance.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares were also up, gaining 34% to $5.20 after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares dropped 30% to $18.33. The company announced topline results from its Phase 3 HARMONi trial.</li>
<li>Shares of Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) were down 19% to $18.08 after the company announced it filed for the resale of up to 121 million shares of class B stock.</li>
<li>CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) was down, falling 33% to $3.0450. CollPlant Biotechnologies announced a $3.6 million registered direct offering priced at-the-market under Nasdaq rules.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $60.58 while gold traded down 0.8% at $3,315.80.
Silver traded down 1.2% to $33.030 on Friday, while copper rose 0.1% to $4.6790.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.14%, while Spain's IBEX 35 Index rose 0.25%. London's FTSE 100 rose 0.64%, Germany's DAX 40 rose 0.27% and France's CAC 40 fell 0.36% during the session.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei falling 1.22%, Hong Kong's Hang Seng Index dipping 1.20%, China's Shanghai Composite Index falling 0.47% and India's BSE Sensex declining 0.22%.
Economics
<ul class="wp-block-list">
<li>The University of Michigan consumer sentiment was revised higher to 52.2 in May versus a preliminary reading of 50.8.</li>
<li>The Chicago PMI declined to 40.5 in May versus 44.6 in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Markets

Trading Ideas

CLGN

DELL

NMAX

SMMT

ULTA

Dow Edges Higher; Dell Shares Fall After Q1 Results

BioLineRx Ltd&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45690392/biolinerx-announces-new-pilot-phase-data-from-phase-2-combination-trial-of-motixafortide-in-first-" rel="noreferrer noopener">Oncology Annual Meeting</a>.
The CheMo4METPANC trial is evaluating motixafortide, cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">pancreatic cancer (PDAC)</a>.
Updated results from the pilot phase indicate that four of eleven patients remained progression-free after more than one year.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" target="_blank" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data</a>
Two patients underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response.
An analysis of pre-and-on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination.
In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer-associated fibroblasts, a potential marker of response.
The pilot clinical trial of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel (N=11) demonstrated an overall response rate (ORR) of 64% (7/11) and a disease control rate (DCR) of 91% (10/11), compared to historical ORR and DCR of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel.
Based on these results, the CheMo4METPANC Phase 2 trial was amended to become a randomized study, with planned enrollment increasing from 30 to 108 patients.
The trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies. The trial will be fully enrolled in 2027, and a prespecified interim analysis is planned for when 40% of PFS events are observed.
Earlier this week, BioLineRx said it reduced operating expense run rate by over 70% beginning&nbsp;January 1, 2025, through the APHEXDA program transfer to Ayrmid and the resulting shutdown of the company&#8217;s U.S. commercial operations in Q4 2024, as well as additional headcount and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45613973/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">other operating expense reductions</a>.
The company completed financing in&nbsp;January 2025, raising gross proceeds of&nbsp;$10 million and reaffirmed cash runway through the second half of 2026.
Jones Trading upgraded BioLine Rx from Hold to Buy and announced a <a target="_blank" href="https://www.benzinga.com/quote/BLRX/analyst-ratings" rel="noreferrer noopener">$12 price target</a>.
Price Action: BLRX stock is up 42.7% at $5.41 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45678673/teva-reaffirms-growth-strategy-eyes-5-billion-innovative-franchise-by-2030" target="_blank" rel="noreferrer noopener">Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030</a></li>
</ul>
Photo by jittawit21 via Shutterstock

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

<h3>Gainers</h3>
<ul>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 171.6% to $2.83 during Friday's regular session. The market value of their outstanding shares is at $53.0 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock moved upwards by 50.92% to $5.72. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 39.78% to $2.78. The company's market cap stands at $48.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.48% to $915.0. The company's market cap stands at $11.9 billion. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares rose 23.0% to $2.62. The company's market cap stands at $146.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 20.47% to $1.74. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock fell 29.5% to $3.2 during Friday's regular session. The market value of their outstanding shares is at $36.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined by 29.48% to $18.48. The market value of their outstanding shares is at $13.7 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock fell 28.41% to $3.9. The market value of their outstanding shares is at $2.8 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 27.38% to $0.49. The market value of their outstanding shares is at $21.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 24.29% to $0.46. The market value of their outstanding shares is at $22.5 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares decreased by 21.01% to $10.98. The company's market cap stands at $91.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

ASBP

EXOZ

HBIO

IMNN

SPRO

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.18% to 42,140.55 while the NASDAQ fell 0.57% to 19,066.89. The S&amp;P 500 also fell, dropping, 0.34% to 5,892.19.
Check This Out: <a href="https://www.benzinga.com/25/05/45640155/wall-streets-most-accurate-analysts-give-their-take-on-3-materials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Consumer staples shares jumped by 0.9% on Friday.
In trading on Friday, energy stocks fell by 0.9%.
Top Headline
The Chicago PMI declined to 40.5 in May versus 44.6 in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Global Interactive Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GITS#NASDAQ">GITS</a>) shares shot up 149% to $2.41.</li>
<li>Shares of Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) got a boost, surging 136% to $0.4735.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares were also up, gaining 79% to $6.95 after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Babcock &amp; Wilcox Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares dropped 33% to $8.74.</li>
<li>Shares of Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) were down 32% to $2.4624.</li>
<li>CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) was down, falling 31% to $3.1201. CollPlant Biotechnologies announced a $3.6 million registered direct offering priced at-the-market under Nasdaq rules.</li>
</ul>
Commodities In commodity news, oil traded down 1.2% to $60.24 while gold traded down 0.9% at $3,313.30.
Silver traded down 1% to $33.075 on Friday, while copper fell 0.4% to $4.6560.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.2%, while Spain's IBEX 35 Index rose 0.3%. London's FTSE 100 rose 0.7%, Germany's DAX 40 rose 0.3% and France's CAC 40 fell 0.3% during the session.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei falling 1.22%, Hong Kong's Hang Seng Index dipping 1.20%, China's Shanghai Composite Index falling 0.47% and India's BSE Sensex declining 0.22%.
Economics
<ul class="wp-block-list">
<li>The University of Michigan consumer sentiment was revised higher to 52.2 in May versus a preliminary reading of 50.8.</li>
<li>The Chicago PMI declined to 40.5 in May versus 44.6 in the previous month.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Earnings

Intraday Update

BURU

BWNB

GITS

MDCX

Nasdaq Down 100 Points; Chicago PMI Dips In May

Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) from Hold to Buy and announces $12 price target.

Upgrades

Jones Trading Upgrades BioLine Rx to Buy, Announces $12 Price Target

<h3>Gainers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock increased by 67.5% to $6.35 during Friday's pre-market session. The market value of their outstanding shares is at $23.6 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock rose 20.19% to $1.25. The market value of their outstanding shares is at $23.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 10.92% to $5.79. The market value of their outstanding shares is at $3.3 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock increased by 10.28% to $1.3. The market value of their outstanding shares is at $20.4 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock moved upwards by 9.98% to $0.98. The market value of their outstanding shares is at $45.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 9.52% to $1.38. The company's market cap stands at $111.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock declined by 23.0% to $3.5 during Friday's pre-market session. The market value of their outstanding shares is at $40.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 20.28% to $0.41. The market value of their outstanding shares is at $3.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 15.95% to $0.28. The market value of their outstanding shares is at $7.7 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares fell 14.8% to $11.17. The company's market cap stands at $366.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 13.23% to $0.36. The company's market cap stands at $1.7 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 13.0% to $0.58. The company's market cap stands at $25.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

ENTO

GNPX

IMAB

NPCE

RVPH

VSEE

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter">raised its FY26 guidance</a>.
UiPath reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of 10 cents per share. The company reported quarterly sales of $356.62 million which beat the analyst consensus estimate of $332.87 million.
UiPath shares jumped 13.2% to $14.65 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) rose 93.4% to $3.50 in pre-market trading after dipping 20% on Thursday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) surged 73.9% to $0.3513 in pre-market trading after jumping 34% on Thursday.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) jumped 64.7% to $6.39 in pre-market trading after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.</li>
<li>ECD Automotive Design, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares jumped 54.4% to $0.4089 in pre-market trading.</li>
<li>Red Robin Gourmet Burgers, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) surged 29.4% to $4.05 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) climbed 28.1% to $2.37 in pre-market trading after the company announced plans to acquire Ucare Inc. in a $150 million all-stock deal.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) gained 17.3% to $1.22 in pre-market trading.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) rose 16.7% to $92.45 in pre-market trading after jumping 172% on Thursday.</li>
<li>Euroholdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHLD#NASDAQ">EHLD</a>) gained 11.9% to $6.85 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) shares fell 49.9% to $0.3511 in pre-market trading after dipping 5% on Thursday.</li>
<li>CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) fell 21.8% to $3.55 in pre-market trading. CollPlant Biotechnologies announced a $3.6 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) fell 21.6% to $2.85 in pre-market trading after dipping 12% on Thursday.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares dipped 18.6% to $0.42 in pre-market trading after gaining 7% on Thursday.</li>
<li>Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares tumbled 18.1% to $2.81 in pre-market trading after the company announced it received a Nasdaq late filing notice.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) declined 16% to $0.3461 in pre-market trading after gaining 5% on Thursday.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) dipped 13.7% to $24.10 in pre-market trading after the company reported first-quarter financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) fell 9.7% to $83.23 in today's pre-market trading after the company reported fourth-quarter results.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 8.8% to $552.00 in pre-market trading after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study didd not.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) fell 8.2% to $20.49 in pre-market trading. Newsmax filed for resale of up to 121 million shares of Class B common stock by selling stockholder.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

BSLK

ECDA

EHLD

ESTC

PATH

REGN

RRGB

SBET

SISI

TIRX

Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

REGN: -13% &#x7C; <a href="https://www.benzinga.com//node/45690708">Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study did not.</a>
&nbsp;
GAP: -18% &#x7C; <a href="https://www.benzinga.com//node/45690678">Gap shares are trading lower after the company reported Q1 financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.</a>
&nbsp;
BLRX: 157% &#x7C; <a href="https://www.benzinga.com//node/45690769">BioLineRx shares are trading higher after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.</a>

Market-Moving News for May 30th

WIIM

BioLineRx shares are trading higher after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
&nbsp;
The CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard-of-care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
Updated results from the pilot phase indicate that four of eleven patients remained progression free after more than one year. Two patients underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven patients treated with the motixafortide combination. In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer associated fibroblasts, a potential marker of response.

BioLineRx Reports Long-Term Tumor Control in Some Patients From New Pancreatic Cancer Combo Trial

BioLine Rx Q1 2025 EPS $0.00 May Not Be Comparable To $(1.20) Estimate, Sales $255.00K Vs. $6.86M YoY

<h3>Companies Reporting Before The Bell</h3>
• Bank of Nova Scotia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNS#NYSE">BNS</a>) is projected to report quarterly earnings at $1.57 per share on revenue of $9.02 billion. 
• Evaxion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) is likely to report quarterly loss at $0.25 per share on revenue of $3.20 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is expected to report quarterly loss at $0.44 per share on revenue of $23.13 million. 
• PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is estimated to report quarterly earnings at $2.49 per share on revenue of $14.17 billion. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is estimated to report quarterly loss at $1.06 per share on revenue of $1.48 million. 
• Champion Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) is projected to report quarterly earnings at $0.76 per share on revenue of $595.42 million. 
• Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is estimated to report earnings for its first quarter. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is projected to report quarterly earnings at $37.03 per share on revenue of $4.41 billion. 
<h3>Companies Reporting After The Bell</h3>
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is likely to report earnings for its first quarter. 
• Senstar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNT#NASDAQ">SNT</a>) is likely to report earnings for its first quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is projected to report earnings for its first quarter. 
• Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) is estimated to report quarterly earnings at $1.04 per share on revenue of $1.05 billion. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is expected to report earnings for its first quarter. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is likely to report earnings for its first quarter. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $274.67 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $680.10 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVAX

OKTA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SHIP

SMTC

SUPV

Earnings Scheduled For May 27, 2025

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-27. Here's a quick overview of what investors should know before the release.
Analysts are estimating that BioLine Rx will report an earnings per share (EPS) of $-1.06.
Investors in BioLine Rx are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 1.35% drop in the share price the following trading session.
Here's a look at BioLine Rx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>-0.10</td>
<td>-0.14</td>
<td>-0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>-0.07</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>9.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1748268107_0.png" alt="eps graph" />
<h3>BioLine Rx Share Price Analysis</h3>
Shares of BioLine Rx were trading at $3.8 as of May 22. Over the last 52-week period, shares are down 87.27%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BLRX/earnings">To track all earnings releases for BioLine Rx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at BioLine Rx's Upcoming Earnings Report

<a href="https://ppubs.uspto.gov/api/pdf/downloadPdf/12291570?requestToken=eyJzdWIiOiJjOTQwM2FiZi00MjE0LTRkZjQtYTZlMC00NTE3NDcwOTMwZDUiLCJ2ZXIiOiI1YWY5ZWZhOC1mMDY4LTQ0M2UtYjQ1YS02MjgxYmJhMTYwMGIiLCJleHAiOjB9" title="https://ppubs.uspto.gov/api/pdf/downloadPdf/12291570?requestToken=eyJzdWIiOiJjOTQwM2FiZi00MjE0LTRkZjQtYTZlMC00NTE3NDcwOTMwZDUiLCJ2ZXIiOiI1YWY5ZWZhOC1mMDY4LTQ0M2UtYjQ1YS02MjgxYmJhMTYwMGIiLCJleHAiOjB9">https://ppubs.uspto.gov/api/pdf/downloadPdf/12291570?requestToken=eyJzdWIiOiJjOTQwM2FiZi00MjE0LTRkZjQtYTZlMC00NTE3NDcwOTMwZDUiLCJ2ZXIiOiI1YWY5ZWZhOC1mMDY4LTQ0M2UtYjQ1YS02MjgxYmJhMTYwMGIiLCJleHAiOjB9</a>

BioLineRx Ltd., Merck Granted U.S. Patent #12291570	Treatment of metastatic pancreatic adenocarcinoma

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 65.3% to $1.67 during Friday's after-market session. The market value of their outstanding shares is at $66.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 9.35% to $1.67. The market value of their outstanding shares is at $3.2 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares rose 7.45% to $0.27. The market value of their outstanding shares is at $22.6 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares moved upwards by 7.08% to $2.87. The market value of their outstanding shares is at $13.1 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 6.66% to $1.28. The company's market cap stands at $23.6 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock moved upwards by 6.63% to $31.48. The market value of their outstanding shares is at $867.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 24.2% to $0.39 during Friday's after-market session. The company's market cap stands at $9.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 15.75% to $0.63. The market value of their outstanding shares is at $7.2 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 12.09% to $1.6. The company's market cap stands at $21.2 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock declined by 10.86% to $3.04. The company's market cap stands at $11.3 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 8.63% to $0.74. The market value of their outstanding shares is at $3.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 7.4% to $0.6. The company's market cap stands at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCDA

BIVI

LENZ

PALI

PLRZ

RNAZ

THAR

12 Health Care Stocks Moving In Friday's After-Market Session

Offerings

Press Releases

BioLineRx Announces $10 Million Registered Direct Offering

Small Cap

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Issues Letter to Shareholders

Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

BioLineRx to Report 2024 Annual Results on March 31, 2025

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

The CHIPS Act and Peraso Inc. (NASDAQ: PRSO): Advancing Semiconductor Innovation and National Security – More Stocks Inside

Comments

BioLine Rx

Vendite allo scoperto

BioLine Rx (NASDAQ:BLRX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO